Malaria is an extremely dangerous and sometimes deadly disease caused primarily by a particular kind of insect that mainly feeds off of mosquitoes. Persons who contract malaria generally are very ill with high fever, vomiting, and fevers. Although the disease is not life threatening or contagious, it is very serious and can cause death if not treated promptly. Since malaria has been responsible for thousands of deaths around the world, it is important to know more about it. The name malaria comes from the word basarial, which means “on the right side of the chest.” Symptoms usually occur 10 days or two weeks after being bitten by an infected mosquito. Some symptoms include high fever, chills, headache, nausea, diarrhea, vomiting, and bleeding.
According to the World Health Organization (WHO), nearly half of the global population is at risk of malaria. This is encouraging healthcare agencies towards addressing this major malady. Moreover, global non-profit organizations such as the Melinda Gates Foundation and PATH are working towards developing preventive measures and saving lives of many in the malaria affected regions. Africa accounts for the 90% of malaria cases and hence, this region is the primary target of launching the first malaria vaccine developed by GlaxoSmithKline plc. Mosquirix received EU approval in 2015 and is presently being examined in Africa as a pilot study.
People in Africa use insecticide-treated mosquito nets and indoor-insecticide spraying for prevention against malarial vectors. According to the World Health Organization (WHO), use of insecticide-treated mosquito nets in Africa increased by 80% during 2010-2015 Moreover, a number of mosquito repellent products (patches, creams, coils, mats, liquids, etc.) are marketed globally. Besides, non-profit organizations offer cheap and often free treatment facilities to the malarial affected population in the region. Also, GSK has pledged to sell the vaccines at a much lower cost forgoing its huge profit margins to support the global malaria eradication programs. Furthermore, with more malarial vaccines under research pipeline, the malaria vaccines market is expected to gain significant growth in near future.
The global malaria vaccines market is expected to be valued at US$ 50.6 million in 2024 and is expected to witness a CAGR of 150.0% during the forecast period (2024 – 2027).
Profitable market opportunities in the malaria vaccines market
Potential for malaria vaccines is estimated to be huge as a large share of population, 90%-95%, at risk of infection in Africa and South East-Asia. Introduction of malaria vaccines for adult population, would be a major breakthrough for the market. Below are certain alarming statistics that embarks the need for a malaria vaccine:
- Artemisinin resistance has been detected in five countries – Laos, Cambodia, Myanmar, Vietnam and Thailand
- Resistance to P. falciparum parasite against the most available anti-malarial medicines is being reported
- According to the National Vector Borne Disease Control Programme, nearly 95% of the population in India reside in malaria endemic areas
- There were 216 million malaria cases globally in 2016 (WHO)
- Africa is the most affected region with 90% of malaria cases and deaths worldwide (WHO)
- Pregnant women, children below 5 years of age, and tourists from countries with low incidence rate of malaria are identified as the most susceptible target population for malaria
The global malaria vaccines market is expected to experience a huge trajectory growth with the launch of first malarial vaccine in near future.
Growing accessibility and government initiatives contributing towards the malaria vaccines market growth
The WHO has established a Global Technical Strategy for Malaria 2016-2030 (GTS) in 2015 with certain defined goals, one of them aimed at eliminating malaria in at least 10 countries. Similarly, the Indian government has established Drug Distribution Centers (DDCs) and Fever Treatment Depots (FTDs) in the rural areas for providing easy access to anti-malarial drugs. Regular monitoring and surveillance by various government programs has helped to reduce malarial cases in India from 2.03 million in 2010 to 1.1 million in 2015. Hence, support from such national and global initiatives will favor the growth of the malaria vaccines market growth over the forecast period.
Many such non-profit organizations and pharmaceutical companies are conducting research on malaria vaccines. Approximately 31 trials are under progress for malaria vaccine development with a few being blood stage projects. Availability of funds and government support programs will encourage commercialization of product with successful trial results, thus boosting the malaria vaccines market growth trajectory.
Table of Contents
- Research Objective and assumption
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet By Vaccines Type
- Market Snippet By Agent
- Market Snippet By Distribution Channel
- Market Snippet By Geography
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- PEST Analysis
- Key Market Developments
- Product Pipeline Analysis
- RTS, S Development Roadmap
- Market Dynamics
- Global Malaria Vaccines Market, By Vaccines Type, 2024 – 2027 (US$ Million)
- Introduction
- Market Share Analysis, 2024 and 2027 (%)
- Y-O-Y Growth Analysis, 2024 – 2027
- Segment Trends
- Pre-Erythrocytic Vaccine
- Introduction
- Market Size and Forecast, and Y-O-Y Growth, 2024 – 2027, (US$ Million)
- Erythrocytic Vaccine
- Introduction
- Market Size and Forecast, and Y-O-Y Growth, 2024 – 2027, (US$ Million)
- Multi-antigen Vaccine
- Introduction
- Market Size and Forecast, and Y-O-Y Growth, 2024 – 2027, (US$ Million)
- Introduction
- Global Malaria Vaccines Market, By Agent, 2024 – 2027 (US$ Million)
- Introduction
- Market Share Analysis, 2024 and 2027 (%)
- Y-O-Y Growth Analysis, 2024 – 2027
- Segment Trends
- Plasmodium Falciparum
- Introduction
- Market Size and Forecast, and Y-O-Y Growth, 2024 – 2027, (US$ Million)
- Plasmodium Vivax
- Introduction
- Market Size and Forecast, and Y-O-Y Growth, 2024 – 2027, (US$ Million)
- Introduction
- Global Malaria Vaccines Market, By Distribution Channel, 2024 – 2027 (US$ Million)
- Introduction
- Market Share Analysis, 2024 and 2027 (%)
- Y-O-Y Growth Analysis, 2024 – 2027
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-O-Y Growth, 2024 – 2027, (US$ Million)
- Clinics
- Introduction
- Market Size and Forecast, and Y-O-Y Growth, 2024 – 2027, (US$ Million)
- Community Centers
- Introduction
- Market Size and Forecast, and Y-O-Y Growth, 2024 – 2027, (US$ Million)
- Introduction
- Global Malaria Vaccines Market, By Geography, 2024 – 2027 (US$ Million)
- Introduction
- Market Share Analysis, By Region, 2024 and 2027 (%)
- Y-O-Y Growth Analysis, For Regions, 2024 – 2027
- North America
- Market Share Analysis, By Country, 2024 and 2027 (%)
- Y-O-Y Growth Analysis, By Country, 2024 – 2027
- U.S.
- Canada
- Europe
- Market Share Analysis, By Country, 2024 and 2027 (%)
- Y-O-Y Growth Analysis, By Country, 2024 – 2027
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Share Analysis, By Country, 2024 and 2027 (%)
- Y-O-Y Growth Analysis, By Country, 2024 – 2027
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Market Share Analysis, By Country, 2024 and 2027 (%)
- Y-O-Y Growth Analysis, By Country, 2024 – 2027
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- Market Share Analysis, By Country, 2024 and 2027 (%)
- Y-O-Y Growth Analysis, By Country, 2024 – 2027
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Market Share Analysis, By Country, 2024 and 2027 (%)
- Y-O-Y Growth Analysis, By Country, 2024 – 2027
- Northern Africa
- Central Africa
- South Africa
- Introduction
View Press Release: https://www.coherentmarketinsights.com/press-release/malaria-vaccines-market-to-surge-past-us-5918-million-by-2024-146
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837